purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation zts earnings call period ending march image source motley fool zoetis zts q earnings callmay etcontents prepared remark question answer call participant prepared remark operatorwelcome first quarter financial result conference call webcast zoetis hosting call today steve frank vice president investor relation zoetis presentation material additional financial table currently posted investor relation section zoetiscom presentation slide managed viewer forwarded automatically addition replay call available approximately two hour conclusion call via dialin investor relation section zoetiscom time participant placed listenonly mode floor open question following presentation operator instruction pleasure turn floor steve frank steve may beginsteve frank vice president investor relation thank operator good morning everyone welcome zoetis first quarter earnings call joined today kristin peck chief executive officer wetteny joseph chief financial officer begin remind slide presented call available investor relation section website remark today include forwardlooking statement actual result could differ materially projection list description certain factor could cause result differ refer forwardlooking statement today press release sec filing including limited annual report form k report form q remark today also include reference certain financial measure prepared accordance generally accepted accounting principle yous gaap reconciliation nongaap financial measure directly comparable yousgaap measure included financial table accompany earnings press release company k filing dated today thursday may nd also cite operational result exclude impact foreign exchange turn call kristin kristin peck chief executive officer thank steve good morning everyone welcome first quarter earnings call today reported outstanding first quarter result underscored steady demand product focused strategy purposedriven colleague delivered operational revenue growth grew adjusted net income operationally line tenet value proposition driven launch osteoarthritis pain franchise yous led way growth operational growth internationally specifically globally librela grew operationally including million sale yous line expectation powerful humananimal bond fueled demand companion animal portfolio growth operationally livestock declined operationally quarter result even amid global uncertainty testament power diverse durable portfolio across market specie therapeutic area also highlight continued rise resilience animal health industry purpose performance rooted science always great disruptor animal health increasingly essential nutrition companionship caregiver demand even highquality innovation mean identified prevalent area unmet veterinary need invested developed manufactured delivered lifechanging product customer waiting take example librela solensia injectable monoclonal antibody treat oa pain dog cat helping million pet return play million dos distributed worldwide providing longlasting relief animal many previously undiagnosed untreated due limitation nsaid nearly dog suffering oa pain globally believe onethird treated scratching surface care cat visiting clinic often fact helping curve clinic fear bonqat first fdaapproved product alleviate anxiety cat mean expanding care historically undermedicalized area market understand social medium forum convening place pet owner connect share also responsibility empower customer make informed decision grounded science data unwavering commitment rigorous safety quality standard earned u trust confidence veterinarian worldwide backed commitment librela solensia safe effective anchored year science used europe three year yous veterinarian center care satisfied librela driven realworld experience consistent feedback hear market research indicates vet globally treat oa earlier treat dog librela available accurately reaffirm safety efficacy therapy doubling working directly veterinarian need product hosting live session chief medical officer expanding online education training deploying capital expand dtc strategy veterinarian continue confident librela evidenced recent blind survey yous vet confirming perception intent prescribe remain unchanged remain confident oa pain could next billion franchise meeting need underserved market growing nearly every metric including adoption penetration reorder rate patient share expanded utilization looking fourweek rolling average yous excited report sale steadily increased april performance speaks power human animal bond discerning pet owner want option work vet find relief best friend beyond oa pain zoetis able lead market key category deeply understand customer need allows u compete existing market create entirely new one science created something completely unique industry billion franchise parasiticides portfolio expanded total market based deep customer insight simparica simparica trio category innovation changed compete today continue gaining share growing market even face competition similarly first recognize new therapy needed treat canine itch safely effectively market foresight changed treatment paradigm revolutionized pet care decade dermatology led three product major lifecycle enhancement including cytopoint first ever animal health monoclonal antibody first chewable apoquel chew believed million market grown billion know customer need today million dog treated allergic itch atopic dermatitis another million remain untreated globally built billion franchise demonstrated durability portfolio continue growing franchise underpinned strong brand equity firstmover advantage lifecycle innovation strong customer relationship led parasiticides dermatology oa pain time innovation created new category animal health seen total industry opportunity expand moving livestock sure saw news week announcement agreement phibro animal health sell global medicated feed additive certain watersoluble product portfolio related asset million deal another great example zoetis disciplined capital allocation strategy focus investment area greatest growth potential innovation aligned key capability confident phibros management global reach product continue expand meet customer need worldwide remain committed livestock sharpen focus core innovative livestock growth area including preventative antibiotic alternative genetics summary year zoetis leading industry commitment innovation invested billion rd since ipo brought product line market science always great disruptor core success delivering innovation veterinarian livestock producer pet owner expect u pursuit science led breakthrough dermatology like cytopoint apoquel chew parasiticides simparica trio latest oa pain librela solensia revolutionizing animal health blazing new trail easy time purposedriven colleague proven ability expand industry leadership forge entirely new market remain committed delivering strong growth innovative franchise diverse portfolio continuing invest future looking ahead remainder increased operational guidance reflects resilience animal health market execution strategic growth priority continue disciplined yet adaptable approach opportunity potential challenge economic shift occurred throughout year turn wettenywetteny joseph chief financial officer thank good morning everyone kristin mentioned outstanding start year driven underlying strength companion animal portfolio particularly innovative product well price growth across specie first quarter generated revenue billion growing reported basis operational basis adjusted net income million grew reported basis operational basis operational revenue growth due underlying strength companion animal portfolio aided impact weak comparative quarter yous companion animal business however majority visibility growth offset headwind related economic condition china impact tough comparative quarter livestock due timing supply certain product last year inventory destocking related yous diagnostics sale model change operational revenue growth price growth volume saw price growth across portfolio price favorably impacted hyperinflationary market especially argentina contributed overall price growth volume growth driven primarily new product including monoclonal antibody oa pain librela solensia well key dermatology product simparica trio segment basis yous posted billion revenue growing quarter international segment reported revenue billion operational growth quarter companion animal portfolio main driver revenue growth q growing operationally growth partially offset livestock declined operational basis saw doubledigit operational companion animal growth yous international segment quarter driven strong performance innovative product contribution volume price simparica trio primary driver growth quarter generating million globally representing operational growth saw strong demand trio well continued growth patient share even competition oa pain mabs also significant contributor growth posting million quarter global growth came impact new launch market yous internationally early launch eu market recent vet survey showed increase muscle therapy expansion moderate oa case key dermatology product grew operationally quarter million global revenue wealth within dermatology driven primarily apoquel franchise seeing solid conversion apoquel chewable including modest impact initial distributor stocking yous cytopoint growth continues driven vet pet owner preference injectable method treatment global companion animal diagnostics portfolio declined operationally decline yous driven distribution model change decline anticipated distribution partner sold remaining inventory due transition directonly model yous diagnostics portfolio yous decline partially offset growth internationally livestock portfolio declined operationally expected driven tough comparative quarter prior year especially yous well impact ongoing economic condition china decline partially offset price growth international market moving revenue growth segment quarter yous revenue billion quarter growing companion animal growth livestock posting decline companion animal performance quarter driven simparica trio key dermatology portfolio impact launch librela yous well impact weak comparative quarter outstanding yous companion animal growth came quarter saw vet clinic visit decreased continue see growth therapeutic visit wellness visit drove decline sale outgrowth retail home delivery continued uptake vet clinic fulfillment based growing pet owner preference alternative channel dynamic expected put continued pressure total vet clinic visit without impacting expectation revenue despite visit decline revenue spend per visit clinic grew respectively reflects continued pet owner willingness pay turning product performance simparica trio posted sale million quarter growing continue market leader triple combination parasiticide space leading footprint across channel allowed u continue drive dosage growth increased compliance even decline wellness visit clinic addition weak comparable period prior year seeing favorable price realization due targeted discount program vet well channel dynamic key dermatology product sale yous million quarter growing saw growth price volume across apoquel cytopoint growth also benefited weak comparable period prior year market demand dermatology product remains high quarter saw growth patient share well higher periodic visit clinic additionally growth retail autoship program continue bolster compliance beginning april made apoquel chewable available distribution partner oa pain mabs librela solensia posted combined million yous sale q librela generated million quarter underlying vet demand continuing build momentum full launch q last year excluding impact initial clinic stocking provided last quarter seeing robust sequential quarter growth librela line expectation continue see good growth penetration well strong reorder rate approaching point positive realworld satisfaction clinic among pet owner remain confident safety efficacy librela also expected performance kristin alluded seen steadily increasing trend trailing fourweek sale average yous even april increased medium attention continue see steady progress solensia yous sale million quarter doubling prioryear q sale indicated feline market need significant development pleased progress thus far solensia marketleading product feline oa pain yous seen significant increase medicalized patient pool since launch yous companion animal diagnostics portfolio declined quarter driven primarily distributor inventory work down following channel strategy change destocking line expectation negligible impact underlying clinic demand yous livestock declined quarter underlying business performance quarter expected result reflective strong comparative period q grew due return supply several product primarily cattle sale swine product declined due decreased sale vaccine well jak poultry saw decline result increased generic competition medicated feed additive product moving international segment revenue grew reported basis excluding impact foreign exchange companion animal grew operationally livestock grew operationally increased sale international companion animal product driven oa pain mabs key dermatology product vaccine small animal parasiticides growth partially offset impact china international oa pain mabs grew operationally million combined revenue quarter international librela sale million growing operationally growth balanced across new launch market firstwave eu market continue see evolution european market seen expansion librelas use moderate oa case according latest vet survey represents majority librela patient europe remain pleased success dtc advertising campaign increasing pet owner awareness oa solensia sale million internationally quarter growing operational basis international key dermatology portfolio grew operationally quarter posting million sale saw doubledigit operational growth across major market driven higher compliance new patient growth also favorably impacted preprice increased buyups japan certain european market international small animal parasiticide portfolio grew operationally driven solensia franchise simparica trio growing operationally million sale trio growth benefited continued uptake europe driven key account penetration field force effectiveness well contribution trio launch china simparica posted million revenue growing operational basis quarter growth partially offset operational decline revolution franchise generates high proportion sale china international livestock grew operationally quarter driven price increase especially high inflationary market price growth partially offset volume decline across specie partially driven tough comparative period prior year due return supply certain livestock product volume decline livestock driven cattle due tough comparable period related supply worsening market condition australia international swine portfolio saw volume decline driven china saw lower hog price well reduction herd size sheep saw decline herd reduction due expected weather condition australia new zealand well supply constraint eight key product mentioned last quarter continue see economic challenge china low consumer spending high urban unemployment reduced spending also seeing slowdown livestock lower pork price smaller herd size impact growth expected moderate late year expect continue see headwind throughout year across companion animal livestock moving rest pl quarter adjusted gross margin declined basis point reported basis compared prior year foreign exchange unfavorable impact basis point reported adjusted gross margin excluding fx saw higher margin due price increase favorable mix lower freight cost partially offset higher manufacturing cost especially hyperinflationary market adjusted operating expense increased operationally driven primarily sga growth operationally mainly due higher compensationrelated expense well increased advertising promotion spend oa pain mabs rd grew operational basis driven higher project spend related recent acquisition well advancement pipeline candidate adjusted effective tax rate quarter decrease basis point primarily due higher benefit yous related foreignderived intangible income favorable jurisdictional mix earnings finally adjusted net income grew operationally despite million headwind growth nonrecurring benefit prioryear royalty settlement adjusted diluted eps grew operationally quarter capital expenditure first quarter million quarter repurchased million zoetis share moving guidance wanted comment recent announcement divest medicated feed additive portfolio certain watersoluble product phibro animal health transaction demonstrates zoetis disciplined capital allocation strategy focus investment innovative solution advance animal health productivity sustainability divestiture allow u remain focused livestock solution including vaccine biologic genetic program aligned strategic priority moving guidance full year mentioned outstanding first quarter highlighted ability deliver multiple source growth performance companion animal especially parasiticides key dermatology franchise exceeded expectation additionally continue pleased progress yous launch librela confident ability meet expectation therefore raising operational guidance provided february earnings call note guidance reflects foreign exchange rate late april updated foreign exchange rate negatively impacted reported revenue guidance approximately reported adjusted net income guidance approximately compared initial guidance issued february year expect revenue billion billion representing range operational growth increase operational growth reflective argentina pricing impact well due performance companion animal parasiticides key dermatology product expect full year operational growth simparica trio doubledigits expect growth key dermatology product high singledigit range stated earlier remain pleased yous launch librela expectation librela year remain unchanged moving pl expect adjusted net income range billion billion representing operational growth finally expect adjusted diluted eps range reported diluted eps range summarize go qa pleased start year reported result reflective various foreign exchangerelated headwind operationally continue deliver growth across key therapeutic area across major market growth highlight diversity dependability allows u continually outpace animal health market additionally continue lead way creating new market launching new innovation increase standard medical care animal hand thing operator open line question operator question answer operatoroperator instruction ask limit one question queue followup operator instruction take first question coming michael ryskin bank america please go aheadmichael ryskin bank america merrill lynch analyst great thanks taking question first want ask guide change seems like many moving piece right fx move got price taking argentina stocking comment apoquel chewable obviously librela early year decide raise guide sort like went see upside risk downside risk go year quick followup question squeeze question margin price strength companion gross margin still little bit weaker quarter raising eps operationally year going gross margin flowthrough companion animal portfolio better thankswetteny joseph chief financial officer happy take mike look pleased outstanding quarter start year clearly delivering operational growth revenue adjusted net income operational perspective could pleased term guidance course put take laid performance quarter think prioryear comp think largely offsetting put take go performance think feed later part question decide go increasing guidance operational perspective look put take clearly performance trio key derm continued growth continue ramp launch librela yous across international market give u lot confidence term underpinning growth saw quarter operational perspective yes easier comp look companion animal business particularly yous talked length last year destocking price timing promotional activity etc also headwind strong comp across livestock particular timing supply last year well china market talking expected well argentina given pricing impact issue australia new zealand take look think probably point tailwind net basis would estimate coming quarter look bottom line operational growth adjusted net income despite royalty settlement last year offsetting element still end sort operational growth range delivered though still early year confidence underlying market demand see across product seeing increased periodic visit clinic dermatology trio despite headtohead competition phenomenal quarter million revenue yous leading well take consideration seeing price realization across globe including increased price hyperinflationary market like argentina give u enough confidence able raise guidance still confident delivering revised guidance today term margin let make sure give cover look headline right gross margin basis point fx nearly basis point headwind think important remind everyone significant devaluation argentina occurred two time last year december well prior august december devaluation actually first quarter keep mind international operation closed book month earlier december actually q seeing impact argentina devaluation play particularly look inventory impact cog cost good sold well lower pl factor actually basispoint expansion operationally gross margin aided way expansion adjusted net income growing operatorour next question come jon block stifel please go aheadjon block stifel financial corp analyst great thanks guy good morning guess ask front well wetteny getting lot question argentina hope clear strength top line big raised guide revenue bps year mentioned bps yearoveryear growth quarter argentina right incremental growth contribution argentina year think everyone like trying figure raise call like ex argentina due market hyperinflationary environment hope clear let know maybe shift gear kristin librela helpful comment april run rate overchecks hear safe drug might issue dog neurological issue would love thought company plan call followup study maybe addressing select aes would great thanks time guyswetteny joseph chief financial officer take argentina question first kristin cover librela look way look said prepared commentary quoted basis point contribution top line argentina quarter say look still early year continue look take price market watch play price volume go hyperinflationary market pegging looking based actuals anticipate still early year take basis point spread year effect could say basis point contribution year account price right kind would look said well basis point raise rest underlying business answer somewhere right certainly contribution growth seeing said expectation derm franchise delivering million growing quarter well trio continues perform really well u would say significant contributor topline guide gave increasing top line basis point term range operational growth argentina piece would say significant contribution underlying business wellkristin peck chief executive officer sure jon take second part question librela mean first really want underscore utmost confidence safety efficacy librela used three year across globe million dog approved country overall look rate reported adverse event per globally think important keep mind single adverse event classified emea guideline rare remain confident safety efficacy product watch reported adverse event carefully important part every pharmaceutical company make sure understand trend seeing remained confident data really want underscore market three year continue watch aes coming clear top adverse event today number one lack efficacy working maybe well wanted polydipsia frequent drinking third polyuria frequent urination one talking remain rare side effect word one hopefully answer questionoperatorour next question come erin wright morgan stanley please go aheaderin wright morgan stanley analyst great thanks another one librela given seller trend mentioning think quarterly progression second quarter also like new patient start like looked since kind medium attention livestock broader rationalization kind business selling feed additive business made sense see opportunity prune portfolio presumably lift longterm topline growth target margin profile improved mix alone focus higher growth higher margin business zoetis look like three five year road could potentially skewed think thankskristin peck chief executive officer sure let wetteny start librela performance question got take livestock question wettenywetteny joseph chief financial officer yeah would happy look delivered million revenue q librela growth prior year clearly yous contributing million big part pleased performance across international market well librela saw really strong sequential quarter growth across international market continue see uptake pleased well surveyed european vet clinic actually indicating seeing case moderate case encouraging continue progress product three year term progression year clearly continue ramp yous kristin said said prepared commentary look rolling fourweek basis quarter beyond quarter april continue see steadily increasing order librela well caused u able confident expectation librela look guidance gave well going get specific quarter quarter would say look million q little stocking number speak length february stocking initial launch fourth quarter two half month end year product launch factor holiday well saw fast penetration plus clinic quickly mean lot stocking gave range somewhere quarter third stocking would say likely high end range factor million year really substantial sequential growth librela said continue see momentum product one thing would remind everyone international number market launched second quarter last year lapping across international market include canada brazil australia japan lapping still continue expect see strong meaningful growth product well sequential growth go rest year would remind term expect progression librelakristin peck chief executive officer sure erin take second question livestock talked many time livestock generally historically industry grown around know grew le period time facing loe draxxin large disease outbreak across globe think seeing wettest last year going year returning historic level think look year expect level wetteny mentioned q good indication look sort comparable remain confident livestock believe end higher end range look divestiture medicated feed additive watersoluble portfolio asset continue disciplined around capital allocation divested pumpkin pet care last year something leadership team continue look every asset want make sure investing highest area growth think something rigorous part manage company think look livestock obviously divestiture medicated feed additive portfolio increase overall growth company overall growth livestock also help overall margin real focus divestiture really doubling investing see great potential livestock industry really playing core strength preventative antibiotic alternative genetics think vaccine biologics new genetic solution continue look portfolio always done every year remain confident livestock especially year ability grow faster marketoperatorour next question coming david westenberg piper sandler please go aheaddavid westenberg piper sandler analyst hi thanks taking question congrats quarter gave lot commentary april librela sale sound like weekonweek build confirm fact clinic administration end market looking versus like stocking sale veterinarian really behind product seems like consumer social medium kind stuff want confirm dt sale advertising track kind change finally could squeeze one term assumption high single digit derm assumption term competitive launch thank much congrats quarterwetteny joseph chief financial officer yes david look take stab kristin may add first look librela sale yous keep mind librela sold direct clinic turnaround fast sort channel dynamic play term seeing seeing week week actually coming directly clinic ordering look dtc continues track said prepared commentary part increase see sga spend really advertising promotion behind pain franchise clearly librela yous big part think derm course pleased performance million soft comp neutralize still see really really strong underlying growth strong demand continue able take price across derm course still early year look particularly back half factoring different scenario around timing competition remain confident ability continue grow franchise postcompetition trio nearterm shortterm promotional activity mindful right factor thinking term land high singledigit range said last time mid high single digit clearly confidence continues increase thereoperatorour next question coming balaji prasad barclays please go ahead balaji line open please check mute function ok take next question brandon vazquez william blair please go aheadbrandon vazquez barclays analyst hey good morning everyone thanks taking question first librela ask two front librela guy talk starting see pocket going maybe severe oa dog used moderate oa population anything guy kind help push market development seems bigger opportunity grows coming year followup second question spending million rd think year nice investor day guy held u last year meaningful update pipeline guy share u either new product lifecycle innovation might coming near medium term thankskristin peck chief executive officer sure wetteny want take first one librela take rd questionwetteny joseph chief financial officer yeah would happy look continue pleased performance librela said yous international complete recent survey vet clinic across european market three year market certainly seeing transition lot moderate case fact vet based survey saying case seeing moderate even mild case coming mix encouraging also contributed increase month therapy going somewhere seven eight month estimating based survey vet progression count anticipate seeing across international market still early yous sort progression would expect continue educate vet product talked continue drive move forward kristinkristin peck chief executive officer sure brandon second question rd yes probably saw strong growth rd quarter really remain confident pipeline many key area mentioned investor day guess little le year ago really investing behind key therapeutic area longlasting monoclonal antibody nearterm launch making announcement today call obviously regard going nearterm launch talked excited look renal look oncology cardiovascular diagnostics continue invest area see huge potential look renal cardiology oncology always said said last year four year plus range nearterm update continue launch product look spoke script bonqat around anxiety cat really important may seem huge product overall unlock rest portfolio get cat clinic sell lot product importantly meet need cat population date undermedicalized know give visibility dying rd think see continued deliver pipeline really innovative product like seeing librela solensia also lifecycle innovation really extend life important franchise longacting monoclonal antibody near termoperatorour next question coming steve scala td cowen please go aheadunknown speaker hi good morning chris steve scala two question first livestock seeing impact ongoing outbreak hn avian influenza second yous companion animal market underlying trend seeing yous pet adoption abandonment rate seeing change share wallet share consumer pet spend medicine versus product category thankskristin peck chief executive officer thanks steve try take wetteny certainly anything missed jump look like continuing watch outbreak hn look portfolio capability stand ready support government customer across globe look potential solution address hn vaccine side diagnostics side date requested think like many peer company stand ready support government authority needed want reassure people mean data come milk safe data came fiss morning reassuring people meat base safe seen impact business whatsoever regard major issue customer real focus supporting making sure focus certainly around biosecurity surveillance detection engaged usda others given diagnostics portfolio well seen impact business date regard yous looking seen significant yous national increase people bringing pet back shelter know isolation overall yous trend pet adopted covid aging continue driver growth yous globally know talk around consumer sentiment really changing obviously seen change sort collar treat thing like really clear talked long time think animal healthcare essential skimping animal healthcare look trend quarter look increase periodic visit wetteny talked reality animal need care getting care look spend per visit yous seeing spend per visit yous mean consumer pet owner want take care animal continue invest look strength humananimal bond one reason say animal health resilient industry people continue invest health pet certainly seeing quarter saw expanded operational guidance year really driven companion animal portfolio expect year welloperatorwell take next question nathan rich goldman sachs please go aheadnathan rich goldman sachs analyst great good morning thanks question first clarification argentina price increase guess price increase referenced coincides december devaluation sound like price increase contemplated initial operational revenue range year guess like think impact going forward would imagine contribution similar balance year guess assuming major change currency dynamic market correct way think derm company decided start selling apoquel chewable distribution could maybe talk factor led decision impact topline margin apoquel well broader portfolio think potential benefit selling portfolio distributionwetteny joseph chief financial officer take first one nathan argentina look clearly devaluation occurred prior u issuing guidance plan continue see ability take price fairly significantly market perhaps beyond factored yes sit forecast fx going going happen argentina hyperinflationary market continue monitor one quarter way second quarter factoring thinking well seeing ability continue sort forecast forecast rest year happen bit measured treat would say portion repeat said earlier portion increase certainly coming would say somewhere third half increase giving term operational guidance coming getting operational lift price rest coming rest underlying business talked would think term derm start see kristin want add look clearly product derm apoquel cytopoint market year seven year respectively level satisfaction product high among vet pet owner launched apoquel chewable important element one preference pet owner perhaps vet palatable chewable see one meeting need market well important part defense strategy anticipate competition derm believe competition likely filmcoated tablet conversion apoquel chewable important u seeing conversion occur across international market particular look europe conversion chewable market last couple year encouraging launched yous time launched librela want look potentially accelerate transition conversion hence went thinking still relatively early little bit contribution quarter perhaps growth saw key derm might two point coming see occur second quarter important part defense strategyoperatorwe take next question balaji prasad barclays please go aheadbalaji prasad barclays analyst good morning everyone apology missing spot earlier also case question repeat librela curious understand messaging changed vet use triage drug want treat mean total addressable market one two help u understand quarterly cadence rest year think understanding q expected weakest quarter second half stronger h back print alter quarterly cadence way thank youkristin peck chief executive officer sure take first question balaji librela wetteny expect take second one quarterly cadence think approaching vet vet center care focus always around ensuring vet educated product understand understand used used etc certainly since lot social medium committed ever make sure vet better access lot education always providing significantly increased education vet access thing done done webinars daily session chief medical officer dr richard goldstein make sure interactive session alwayson customer support team think really seeing regard vet feel product confidence access education need look seeing strongly positive experience pet vet really confident product wetteny mentioned confidence prescribing product confidence safety efficacy product talked invest lot zoetis veterinary education always vet operation every market think something strength clearly social medium doubled ensure access veterinary education make sure vet want understand access expert internally well external kols best understand product underscore confidence product talked fact continue believe product category librela librela solensia continue commit billion franchise zoetis really rooted safety efficacy product investment putting vet pet owner make sure understand productwetteny joseph chief financial officer yeah balaji term quarterly cadence answer question specifically respect librela mean overall certainly recap conversation look clearly million contribution first quarter keep mind continue see really strong growth across international market grew quarter well continue drive growth u get ultraspecific term exact contribution quarter go would expect continue ramp million year course fourth quarter term percentage growth lapping million delivered fourth quarter first quarter launchoperatorthank take next question glen santangelo jefferies please go aheadglen santangelo jefferies analyst yeah thanks taking question hey kristin obviously outlook trio derm continues encouraging given recent launch bi elanco launch presumably may coming second half could look second kind curious anticipate sort noticeable shift competitive landscape anything think might impact ability take price reason ask getting concerned increasing competition weakening consumer time maybe would impact company ability take price increase consistent done historically sort highlevel commentary think would helpful thankskristin peck chief executive officer sure start wetteny certainly build one remain confident really based historical performance think look invest lifecycle innovation across franchise let u clear guy patis entered simparica simparica trio facing competition leader parasiticide grew share look q yous even strong competition continue grow share remain confident continue grow parasiticides dermatology franchise even competition mean para always competitive space company operating think strength obviously vet strength pet owner really seeing tremendous growth franchise trio derm alternative channel home delivery retail see great strength look autoship continue increase autoship absolutely increase compliance think really important look example alternative channel grew little bit weaker comp look last year even adjust plus growth alternative channel really believe continue grow franchise based strength product strength portfolio lifecycle innovation look chewable well leveraging new channel benefit increased compliance back confidence know wetteny want add anything thatwetteny joseph chief financial officer look thing would say two thing one seeing weakening consumer saw u post high doubledigit growth across trio key derm franchise even normalize tailwind last year still high doubledigit growth across certainly demonstrates continued demand product innovation one would say look look ahead going give guidance specific confident ability grow face competition shortterm promotional activity might impact beyond confident product see label going compete againstoperatorwell take next question chris schott jp morgan please go ahead chris schott jpmorgan chase company analyst right great thanks much two question continuing trio quantify channel dynamic benefit saw give u little color maybe size second one librela yous expect similar dynamic yous saw ex yous initial uptake severe oa pet think would maybe little bit le sensitive headline seen past month moderate piece business happening kind year two yous market thinking different severe moderate may scaling kind simultaneously thanks muchkristin peck chief executive officer sure thanks chris let take wetteny trio question follow librelawetteny joseph chief financial officer yeah absolutely look short answer channel dynamic seeing mentioned moment ago dynamic last year quarter saw destocking coming promotional timing promotion prior year prepriced buyups provide tailwind posted growth trio globally percentage growth yous million growing say precision would say internal estimate factor tailwind last year may account half growth seeing still remaining significant growth trio channel dynamic term inventory speak current yearkristin peck chief executive officer sure second question regard librela yous mean seen historically europe market launched first often put severe dog desperate new therapy initially moving moderate learned lesson three year europe making sure launch yous get moderate think early experience trial example yous made sure balance mild moderate severe case experience see impact product even look data wetteny spoke earlier outside yous patient right moderate mild moderate case think tremendous growth seeing also increase compliance compliance seven eight month six seven month outside yous goal launching yous designed early experience trial market vet make sure product firstline therapy mild moderate severe case making sure get conversion mild moderate similar europe faster yous certainly focus think growing brand yousoperatorthank take final question navann ty bnp please go aheadnavann ty exane bnp paribas analyst hi good morning thanks taking question thanks color librela followup earliest vet online education session many vet approximately reach far also interested early dialogue fda common surveillance product launch far thank youkristin peck chief executive officer sure thank regard first question vet reached tech bulletin letter directly chief medical officer almost every vet yous vet customer yous think really critical vet join example open office hour chief medical officer richard goldstein invited vet webinars really working veterinary operation group every area across yous make sure access internal external thousand vet attended webinars date something normally obviously put urgency make sure way engage make sure veterinarian question answered think look fact fourweek trailing sale continue accelerate wetteny mentioned demonstration vet feel getting education need confidently prescribe product appropriately regard question regard interaction fda know covering u regular conversation fda time normal course business company launch new brand expand sharing information yous dialogue around sharing global information usual course would launch product honestly even product market year continue usual course collaborate fda make sure information need nothing ordinary normal engagement fdaoperatorand question time turn call speaker closing remarkskristin peck chief executive officer thank sorry back thank look really want thank everyone joining today want reiterate outstanding performance quarter really want thank colleague commitment hopefully see focus creating shareholder value think strong start look forward continued momentum customer obsessed unrivaled rd investment expanded manufacturing capability worldclass purposedriven colleague everything zoetis aimed anticipating addressing believe pressing need veterinary care even widely recognized many others scientific breakthrough firmly established u trusted preferred partner customer continue invest talent pipeline capability support zoetis future growth remain committed safety efficacy product industryleading product treatment change life based track record performance think customer agree well thanks much joining u look forward engaging throughout quarteroperatoroperator signoff duration minutescall participantssteve frank vice president investor relationskristin peck chief executive officerwetteny joseph chief financial officermichael ryskin bank america merrill lynch analystjon block stifel financial corp analysterin wright morgan stanley analystdavid westenberg piper sandler analystbrandon vazquez barclays analystunknown speakernathan rich goldman sachs analystbalaji prasad barclays analystglen santangelo jefferies analystchris schott jpmorgan chase company analystnavann ty exane bnp paribas analyst zts analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position recommends zoetis motley fool disclosure policy